A Phase III Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment
Phase of Trial: Phase III
Latest Information Update: 23 Dec 2018
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 06 Dec 2018 Planned End Date changed from 4 Oct 2018 to 16 Sep 2019.
- 06 Dec 2018 Planned primary completion date changed from 4 Oct 2018 to 16 Sep 2019.
- 03 Nov 2017 New trial record